Top1031

Pharmacy Portfolio II DST

Retail pharmacy property · sponsored by Inland Private Capital

Historical · soldSold Jan 2022, as reported by Inland Private Capital · last Form D Apr 4, 2012Sponsor source (opens in a new tab)

Pharmacy Portfolio II DST was a DST sponsored by Inland Private Capital that owned a retail pharmacy property. Inland Private Capital sold the property in Jan 2022, as reported by the sponsor.

How it ended

Sold, result reported by the sponsor

Sold Jan 2022.

Total return
156.6% as reported by the sponsor
Date
Jan 5, 2022
Held
7.8 years

Sponsor document (opens in a new tab)

Inland Private Capital has 8 active offerings on record →

Key facts

Minimum investment
$25,000
From the Form D
Offering size
$14,636,594
Equity offered, per the Form D
Sold
100%
Form D, Apr 4, 2012; the % is our arithmetic
Investors reported
99
Form D, Apr 4, 2012
Selling commissions
$1,024,562 · 7.0% of offering
Form D Item 15; the % is our arithmetic
Financing
Leveraged. This offering reports mortgage debt on the property.
How it is financed ↓
Offered under
Rule 506(b)
General advertising and solicitation are not permitted under this exemption.

Figures come from SEC Form D filings unless a source is cited. Sponsor-stated figures are as reported by the sponsor; Top1031 does not independently audit them. On a 45-day clock? Find day 45 and day 180 →

Using this record to judge the sponsor? A licensed 1031 specialist from our affiliated partner can talk it through with you.

Ask a 1031 specialist about this recordFree. About: Pharmacy Portfolio II DST. Top1031 is not a broker-dealer.

What did Pharmacy Portfolio II DST own?

Pharmacy Portfolio II DST holds six Walgreens pharmacies spread across six states: Gallup, New Mexico; Normal, Illinois; Somerset, Massachusetts; Spokane, Washington; Villa Rica, Georgia; and Waynesburg, Pennsylvania. 2 No source located states when the buildings were built or acquired, or what Inland paid for them.

Property size
6 Walgreens properties; 85,669 sq ft total (14,744, 14,486, 13,569, 14,400, 13,650, and 14,820 sq ft respectively)

Tenant and lease terms are not in the SEC filings or cited sources.

How was it financed, and what did it cost to sell?

This Trust used leverage: a mortgage loan funded part of the acquisition, non-recourse to the Trust apart from specified carve-outs, and scheduled to mature July 5, 2026. 7

Debt

Financing
Leveraged. This offering reports mortgage debt on the property.

Costs and terms from the Form D

Selling commissions
$1,024,562 · 7.0% of offering
Finders’ fees
$0
Paid to officers, directors and promoters
$1,977,822 · 13.5% of offering
Form D Item 16
Broker-dealers named in the Form D
28 named in the Form D
Show the firms

Individual representatives named in Item 12 are not listed.

Date of first sale
Sep 21, 2011
Minimum investment
$25,000

Form D Item 15 and Item 16 amounts may be the issuer’s estimates; each percentage is Top1031’s arithmetic on two Form D figures. Item 16 can overlap Item 15, so Top1031 does not add them together. The issuer marked these amounts as an estimate.

What does the SEC record show?

The original Form D recorded a first sale of September 21, 2011, and four amendments followed, each updating the amount sold and the investor count. 1 The Rule 506(b) route used here bars general advertising, so interests went to accredited investors — those meeting SEC income or net-worth tests — through existing relationships.

Legal Trust name
Pharmacy Portfolio II DST
SEC CIK
1530173
First Form D
Oct 11, 2011
Latest Form D
Apr 4, 2012
Filings on record
5
Offered under
Rule 506(b)
General advertising and solicitation are not permitted under this exemption.
Source filing
Read the filings on SEC EDGAR

SEC Form D filings, newest first

FiledFormOffering amountAmount soldInvestors
Form D/A$14,636,594
$14,636,594+$4,543,629
99+19
EDGAR
Form D/A$14,636,594
$10,092,965+$5,383,599
80+24
EDGAR
Form D/A$14,636,594
$4,709,366+$1,400,505
56+12
EDGAR
Form D/A$14,636,594
$3,308,861+$1,718,133
44+21
EDGAR
Form D$14,636,594
$1,590,728
23
EDGAR

Amounts, investor counts and minimums are as filed with the SEC on Form D. The change lines are Top1031’s arithmetic between consecutive filings; a new Form D notice starts a new count.

A Form D is the notice a sponsor files when it starts raising money. A Form D filing does not mean the SEC approved, endorsed, or verified the offering.

Common questions

What happened to Pharmacy Portfolio II DST?
Pharmacy Portfolio II DST is a Historical offering. Sold Jan 2022, as reported by Inland Private Capital.
Did the January 2022 eight-property Walgreens sale end this Trust?
Not on the record. Inland's January 5, 2022 release describes eight Walgreens properties in Arkansas, Michigan, Missouri, and Tennessee sold for $37 million on behalf of Pharmacy Sale Leaseback II DST — a different program. This Trust holds six pharmacies in six other states, so no disposition is confirmed for it.
Who are the tenants?
Walgreen Co. is named as tenant at the Gallup, Normal, Spokane, and Villa Rica pharmacies, and Walgreen Eastern Co., Inc. at Somerset and Waynesburg. Sponsor materials state Walgreens is either the tenant or the guarantor under each lease. Sources located do not state the lease type, so triple-net status must be checked in the offering documents.
Was this Trust financed with debt?
Yes. Inland's executive summary states the acquisition was funded in part with a mortgage loan, non-recourse to the Trust subject to carve-outs, with a stated maturity of July 5, 2026. No source located confirms what happened at that maturity date.
Why do the offering size figures differ between sources?
The SEC Form D states one total offering amount, while Inland's executive summary lists total DST Interests of $14,490,228. The two figures are reported as stated and are not reconciled by any source located; the difference is a question for the sponsor and the offering documents.

In the news

Sources

Show sources (11)Hide sources (11)

These links support the record as a whole; individual details may come from different sources.

DST interests are illiquid private securities. You may lose some or all of your investment. Distributions, tax treatment, and exit timing are not guaranteed. Review the current offering documents before investing.